Arcus Biosciences Inc. Insider Trading

RCUS

Last 12 months

Insiders sold $11.4M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Feb 2025.

Net open-market

−$11.4M

0 buys · 19 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Feb 2025

Feb 27, 2025

Get an email when RCUS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 21	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	2,827	$30.00	85K	6.7%	Form 4
Jul 9 – 10	Juan C. Jaen President	Sold10b5-1 plan 3 parts	68,569	$29.63 average	$2.03M	5.4%	Form 4
Jun 22 – 24	Juan C. Jaen President	Sold10b5-1 plan 4 parts	31,431	$27.92 average	878K	2.4%	Form 4
Jun 1	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	2,562	$25.77	66K	6.1%	Form 4
May 11	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan	7,763	$25.63	199K	8.4%	Form 4
Jan 5	Juan C. Jaen President	Sold10b5-1 plan 3 parts	31,823	$21.41 average	681K	2.4%	Form 4
Dec 31, 2025	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan	6,552	$23.38	153K	8.8%	Form 4
Dec 16, 2025 – Dec 18, 2025	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan 3 parts	8,832	$22.13 average	195K	32%	Form 4
Dec 16, 2025 – Dec 17, 2025	Richard Markus Chief Medical Officer	Sold10b5-1 plan 2 parts	9,546	$22.01 average	210K	13%	Form 4
Dec 16, 2025 – Dec 17, 2025	Carolyn C. Tang General Counsel	Sold10b5-1 plan 2 parts	14,468	$22.01 average	318K	10%	Form 4
Dec 16, 2025 – Dec 17, 2025	Jennifer Jarrett Chief Operating Officer	Sold10b5-1 plan 2 parts	21,208	$22.01 average	467K	9.9%	Form 4
Dec 16, 2025 – Dec 17, 2025	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan 2 parts	12,662	$22.01 average	279K	15%	Form 4
Dec 16, 2025 – Dec 17, 2025	Juan C. Jaen President	Sold10b5-1 plan 2 parts	21,208	$22.01 average	467K	1.6%	Form 4
Dec 16, 2025 – Dec 17, 2025	Terry J Rosen Chief Executive Officer	Sold10b5-1 plan 2 parts	54,691	$22.01 average	$1.2M	2.4%	Form 4
Dec 4, 2025	Juan C. Jaen President	Sold10b5-1 plan	82,997	$24.71	$2.05M	5.9%	Form 4
Nov 26, 2025	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	1,900	$26.00	49K	6.5%	Form 4
Nov 26, 2025	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan	5,000	$25.00	125K	5.4%	Form 4
Nov 17, 2025 – Nov 18, 2025	Juan C. Jaen President	Sold10b5-1 plan 3 parts	50,000	$20.26 average	$1.01M	3.4%	Form 4
Nov 7, 2025	Jennifer Jarrett Chief Operating Officer	Sold10b5-1 plan	50,291	$18.97	954K	19%	Form 4
Oct 30, 2025	Juan C. Jaen President	Sold10b5-1 plan	4,314	$20.32	88K	0.3%	Form 4
Oct 28, 2025 – Oct 29, 2025	Juan C. Jaen President	Sold10b5-1 plan 4 parts	96,859	$20.76 average	$2.01M	6.2%	Form 4
Oct 28, 2025	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan	5,000	$20.00	100K	5.1%	Form 4
Oct 6, 2025 – Oct 8, 2025	Jennifer Jarrett Chief Operating Officer	Sold10b5-1 plan 2 parts	50,292	$14.92 average	751K	19%	Form 4
Sep 29, 2025	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	2,831	$13.00	37K	9.4%	Form 4
Sep 5, 2025	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	1,579	$11.88	19K	5.0%	Form 4
Feb 27, 2025	Yasunori Kaneko Director	Bought	20,000	$10.06	201K	2.2%	Form 4
Feb 27, 2025	Terry J Rosen Chief Executive Officer	Bought	19,800	$10.18	202K	0.8%	Form 4
Feb 18, 2025	Gilead Sciences, Inc. Large holder	Bought	1,363,636	$11.00	$15M	4.5%	Form 4
Dec 31, 2024	Robert C. Goeltz II Chief Financial Officer	Sold10b5-1 plan	3,594	$15.00	54K	5.6%	Form 4
Dec 2, 2024	Alexander Azoy Chief Accounting Officer	Sold10b5-1 plan	201	$15.32	3K	1.0%	Form 4

Aug 2110b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 2,827 at $30.00
85K
6.7% of stake
Jul 9 – 1010b5-1 plan
Juan C. Jaen
President · sold 68,569 at avg $29.63
$2.03M
5.4% of stake
Jun 22 – 2410b5-1 plan
Juan C. Jaen
President · sold 31,431 at avg $27.92
878K
2.4% of stake
Jun 110b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 2,562 at $25.77
66K
6.1% of stake
May 1110b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 7,763 at $25.63
199K
8.4% of stake
Jan 510b5-1 plan
Juan C. Jaen
President · sold 31,823 at avg $21.41
681K
2.4% of stake
Dec 31, 202510b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 6,552 at $23.38
153K
8.8% of stake
Dec 16, 2025 – Dec 18, 202510b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 8,832 at avg $22.13
195K
32% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Richard Markus
Chief Medical Officer · sold 9,546 at avg $22.01
210K
13% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Carolyn C. Tang
General Counsel · sold 14,468 at avg $22.01
318K
10% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Jennifer Jarrett
Chief Operating Officer · sold 21,208 at avg $22.01
467K
9.9% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 12,662 at avg $22.01
279K
15% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Juan C. Jaen
President · sold 21,208 at avg $22.01
467K
1.6% of stake
Dec 16, 2025 – Dec 17, 202510b5-1 plan
Terry J Rosen
Chief Executive Officer · sold 54,691 at avg $22.01
$1.2M
2.4% of stake
Dec 4, 202510b5-1 plan
Juan C. Jaen
President · sold 82,997 at $24.71
$2.05M
5.9% of stake
Nov 26, 202510b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 1,900 at $26.00
49K
6.5% of stake
Nov 26, 202510b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 5,000 at $25.00
125K
5.4% of stake
Nov 17, 2025 – Nov 18, 202510b5-1 plan
Juan C. Jaen
President · sold 50,000 at avg $20.26
$1.01M
3.4% of stake
Nov 7, 202510b5-1 plan
Jennifer Jarrett
Chief Operating Officer · sold 50,291 at $18.97
954K
19% of stake
Oct 30, 202510b5-1 plan
Juan C. Jaen
President · sold 4,314 at $20.32
88K
0.3% of stake
Oct 28, 2025 – Oct 29, 202510b5-1 plan
Juan C. Jaen
President · sold 96,859 at avg $20.76
$2.01M
6.2% of stake
Oct 28, 202510b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 5,000 at $20.00
100K
5.1% of stake
Oct 6, 2025 – Oct 8, 202510b5-1 plan
Jennifer Jarrett
Chief Operating Officer · sold 50,292 at avg $14.92
751K
19% of stake
Sep 29, 202510b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 2,831 at $13.00
37K
9.4% of stake
Sep 5, 202510b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 1,579 at $11.88
19K
5.0% of stake
Feb 27, 2025
Yasunori Kaneko
Director · bought 20,000 at $10.06
201K
2.2% of stake
Feb 27, 2025
Terry J Rosen
Chief Executive Officer · bought 19,800 at $10.18
202K
0.8% of stake
Feb 18, 2025
Gilead Sciences, Inc.
Large holder · bought 1,363,636 at $11.00
$15M
4.5% of stake
Dec 31, 202410b5-1 plan
Robert C. Goeltz II
Chief Financial Officer · sold 3,594 at $15.00
54K
5.6% of stake
Dec 2, 202410b5-1 plan
Alexander Azoy
Chief Accounting Officer · sold 201 at $15.32
3K
1.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RCUS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RCUS

CompareIntrinsic value

GYREGyre Therapeutics Inc.

$4.44+0.00%18

SPRYArs Pharmaceuticals Inc

$3.05+0.00%40

CYTKCytokinetics, Incorporated

$63.60+2.07%10

ETONEton Pharmaceuticals Inc.

$50.72-0.45%75

TBPHTheravance Biopharma Inc.

No recent price82

ASRTAssertio Holdings Inc.

$9.09+0.28%10

SEPNSepterna, Inc.

$47.88+9.57%46

AGIOAgios Pharmaceuticals Inc.

$31.38+0.58%40

Held by ETFs

RCUS is in 65 US ETFs. The largest of them, with RCUS's weight in each:

Spot a number that looks wrong? Check it in RCUS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RCUS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.